Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction

Journal of the American College of Cardiology

Volumn 69, Issue 11, 2017, Pages 1386-1395

  Serban, Maria Corina ^a,b   Colantonio, Lisandro D ^a   Manthripragada, Angelika D ^c   Monda, Keri L ^c   Bittner, Vera A ^d   Banach, Maciej ^e   Chen, Ligong ^a   Huang, Lei ^a   Dent, Ricardo ^f   Kent, Shia T ^a   Muntner, Paul ^a   Rosenson, Robert S ^g  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c AMGEN INC   (United States)

^d University of Alabama at Birmingham   (United States)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

^f Esperion Therapeutics Inc   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

coronary heart disease; mortality; myocardial infarction; statins

Indexed keywords

ATORVASTATIN; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADVERSE OUTCOME; AGE DISTRIBUTION; AGED; ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; ICD-9; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICATION COMPLIANCE; MONOTHERAPY; PATIENT COMPLIANCE; RECURRENT DISEASE; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; RISK ASSESSMENT; VERY ELDERLY; EPIDEMIOLOGY; MORTALITY; MYOCARDIAL INFARCTION; SECONDARY PREVENTION; UNITED STATES;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICATION ADHERENCE; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; SECONDARY PREVENTION; UNITED STATES;

EID: 85015211149     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.12.036     Document Type: Article

References (38)

1. 1 Cholesterol Treatment Trialists Collaboration. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005), 1267–1278.
2. 2 Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.
3. 3 Zhang, H., Plutzky, J., Skentzos, S., et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med 158 (2013), 526–534.
4. 4 Mancini, G.J., Baker, S., Bergeron, J., et al. Diagnosis, prevention and management of statin adverse effects and intolerance: Canadian Consensus Working Group update (2016). Can J Cardiol 32:Suppl 7 (2016), S35–S65.
5. 5 Tong, L.S., Hu, H.T., Zhang, S., Yan, S.Q., Lou, M., Statin withdrawal beyond acute phase affected outcome of thrombolytic stroke patients: an observational retrospective study. Medicine (Baltimore), 94, 2015, e779.
6. 6 Colantonio, L.D., Kent, S.T., Huang, L., et al. Algorithms to identify statin intolerance using Medicare administrative claim data. Cardiovasc Drugs Ther 30 (2016), 525–533.
7. 7 Arca, M., Pigna, G., Treating statin-intolerant patients. Diabetes Metab Syndr Obes 4 (2011), 155–166.
8. 8 Bitzur, R., Cohen, H., Kamari, Y., Harats, D., Intolerance to statins: mechanisms and management. Diabetes Care 36:Suppl 2 (2013), S325–S330.
9. 9 Fitchett, D.H., Hegele, R.A., Verma, S., Cardiology patient page. Statin intolerance. Circulation 131 (2015), e389–e391.
10. 10 Rosenson, R.S., Baker, S.K., Jacobson, T.A., Kopecky, S.L., Parker, B.A., The National Lipid Association's muscle safety expert P. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 8 (2014), S58–S71.
11. 11 Choudhry, N.K., Shrank, W.H., Levin, R.L., et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care, 15, 2009, 457.
12. 12 Romano, P.S., Roos, L.L., Jollis, J.G., Presentation adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 46 (1993), 1075–1079.
13. 13 Gu, Q., Burt, V.L., Dillon, C.F., Yoon, S., Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health and Nutrition Examination Survey, 2001 to 2010. Circulation 126 (2012), 2105–2114.
14. 14 Nau DP. Proportion of days covered (PDC) as a preferred method of measuring medication adherence. PQ alliance (Ed)Pharmacy Quality Alliance, Springfield, VA (2012). Available at: http://www.pqaalliance.org/images/uploads/files/PQA%20PDC%20vs%20%20MPR.pdf. Accessed February 6, 2017.
15. 15 Fine, J.P., Gray, R.J., A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94 (1999), 496–509.
16. 16 Pedersen, T.R., Kjekshus, J., Berg, K., et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994 Atheroscler Suppl 5 (2004), 81–87.
17. 17 Sacks, F.M., Pfeffer, M.A., Moye, L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (1996), 1001–1009.
18. 18 Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998), 1349–1357.
19. 19 Smith, S.C., Benjamin, E.J., Bonow, R.O., et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 124 (2011), 2458–2473.
20. 20 Baigent, C., Keech, A., Kearney, P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005), 1267–1278.
21. 21 Rosenson, R.S., Kent, S.T., Brown, T.M., et al. Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. J Am Coll Cardiol 65 (2015), 270–277.
22. 22 Hirsh, B.J., Smilowitz, N.R., Rosenson, R.S., Fuster, V., Sperling, L.S., Utilization of and adherence to guideline-recommended lipid-lowering therapy after acute coronary syndrome: opportunities for improvement. J Am Coll Cardiol 66 (2015), 184–192.
23. 23 Gamboa, C.M., Safford, M.M., Levitan, E.B., et al. Statin underuse and low prevalence of LDL-C control among US adults at high risk of coronary heart disease. Am J Med Sci 348 (2014), 108–114.
24. 24 Maddox, T.M., Chan, P.S., Spertus, J.A., et al. Variations in coronary artery disease secondary prevention prescriptions among outpatient cardiology practices: insights from the NCDR (National Cardiovascular Data Registry). J Am Coll Cardiol 63 (2014), 539–546.
25. 25 Ganga, H.V., Slim, H.B., Thompson, P.D., A systematic review of statin-induced muscle problems in clinical trials. Am Heart J 168 (2014), 6–15.
26. 26 Parker, B.A., Capizzi, J.A., Grimaldi, A.S., et al. Effect of statins on skeletal muscle function. Circulation 127 (2013), 96–103.
27. 27 Cohen, J.D., Brinton, E.A., Ito, M.K., Jacobson, T.A., Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol 6 (2012), 208–215.
28. 28 Nissen, S.E., Stroes, E., Dent-Acosta, R.E., et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 randomized clinical trial. JAMA 315 (2016), 1580–1590.
29. 29 Wilt, T.J., Bloomfield, H.E., MacDonald, R., et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Inter Med 164 (2004), 1427–1436.
30. 30 Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994), 1383–1389.
31. 31 Wei, M.Y., Ito, M.K., Cohen, J.D., Brinton, E.A., Jacobson, T.A., Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol 7 (2013), 472–483.
32. 32 Mampuya, W.M., Frid, D., Rocco, M., et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J 166 (2013), 597–603.
33. 33 Banach, M., Rizzo, M., Toth, P.P., et al. Statin intolerance—an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 11 (2015), 1–23.
34. 34 Guyton, J.R., Bays, H.E., Grundy, S.M., Jacobson, T.A., The National Lipid Association Statin Intolerance Panel. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol 8 (2014), S72–S81.
35. 35 The Administration on Aging, Administration for Community Living. A profile of older Americans: 2013. Washington DC: U.S. Department of Health and Human Services, 2014. Available at: http://www.aoa.acl.gov/aging_statistics/profile/index.aspx. Accessed March 23, 2015.
36. 36 Mirel, L.B., Wheatcroft, G., Parker, J.D., Makuc, D.M., Health characteristics of Medicare traditional fee-for-service and Medicare Advantage enrollees: 1999-2004 National Health and Nutrition Examination Survey linked to 2007 Medicare data. Natl Health Stat Rep, 2012, 1–12.
37. 37 Colantonio, L.D., Kent, S.T., Kilgore, M.L., et al. Agreement between Medicare pharmacy claims, self-report, and medication inventory for assessing lipid-lowering medication use. Pharmacoepidemiol Drug Saf 25 (2016), 827–835.
38. 38 Bruckert, E., Hayem, G., Dejager, S., et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drug Ther 19 (2005), 403–414.